Overall verdict
Sell
1.5/10
1-year performance
+134.18%
Score breakdown
Up 134.2% over 1 year, 44% of the 52-week range.
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Phase IIb and 3 Phase I clinical trial designed to evaluate the safety and efficacy of GLSI-100 in HER2 positive breast cancer patients.
Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Sector
Health Care
Industry
Biotechnology
Primary listing
Nasdaq
United States
CEO
Snehal Patel
Founded
2006
Employees
13
Revenue / employee
0 USD
Next earnings
March 19, 2027 (estimated)
Institutional holders
- BlackRock, Inc.3.49%
- GEODE CAPITAL MANAGEMENT, LLC1.28%
- STATE STREET CORP1.09%
- GOLDMAN SACHS GROUP INC0.39%
- Bank of New York Mellon Corp0.33%
- MORGAN STANLEY0.13%
- FMR LLC0.04%
- JPMORGAN CHASE & CO0.03%
- Rest of the register93.24%
8 13F filings as of September 30, 2026: US managers above $100M, filed up to 45 days after quarter end. No insiders, no retail. A share on loan is declared by its lender and by whoever bought it from the short seller, so the total can exceed 100%.
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
34.10 USD
52-week low
7.78 USD
1-year performance
134.18%
Rising
Year-to-date performance
-9.54%
Rising
Drawdown
-43.55%
Major drawdown
Position in the 52-week range
44% of range
ROIC -10656.2%, ROE -10656.2%.
Net margin
—
Sector -213.59%|S&P 13.35%
Gross margin
—
Return on equity (ROE)
-10656.22%
Negative
Sector -55.30%|S&P 16.98%
Return on invested capital (ROIC)
-10656.22%
Negative
Free cash flow margin (FCF)
—
Revenue (trailing 12 months)
0 USD
Revenue growth (1y)
—
Revenue growth (3y)
—
EPS growth (1y)
—
EPS CAGR (5y)
—
EPS revisions (3 months)
—
Valuation
0.0/10The company loses money, so no valuation multiple can be read: a negative P/E is not a discount.
P/E (TTM)
—
N/A (loss)
Sector 11.0x|S&P 22.1x
Forward P/E (adjusted)
—
N/A (loss)
EV / EBITDA
—
N/A (loss)
Sector 16.5x|S&P 14.9x
PEG
—
Sector 0.38|S&P 0.84
Market cap
283M USD
Net debt / EBITDA
—
Gearing (net debt / equity)
—
Cash
5.9M USD
Cash / market cap
2.09%
Stretched
Net debt
-5.9M USD
Equity
-1.7M USD
Closed daily candles, 2 years
Last close on November 20, 2026: 19.25 USD
- MM2016.95
- MM5016.86
- MM20020.74
- RSI 1458.4
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-4.88%
200-day average slope, 3 months
-0.04%
50-day average slope, 1 month
+1.24%
Price structure
higher-low
Bullish RSI divergence
No
20-day volatility
9.73 % per day
Volatility change
+65.51%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | -1.48 (2) | — | 0 (2) | — | -21 (1) |
| 2027 | -1.80 (2) | — | 0 (2) | — | -22 (1) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 18, 2026.
Same sub-industry: 797 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ALERS | 4.5 | 4.5 | 284M USD | 36.9x | 4.2 % | 9.1 % | 3.7 % | -0.1x | 2.0 % | 8.2 % | ||
| 2 | BNTC | 4.0 | N/A | 286M USD | Not meaningful (loss) | — | — | -37.5 % | 3.2x | -6.2 % | -40.5 % | ||
| 3 | SPRY | 2.7 | 3.0 | 298M USD | Not meaningful (loss) | -163.6 % | 16.0 % | -112.7 % | 0.1x | -61.5 % | -59.0 % | ||
| 4 | 7630 | 2.7 | 2.7 | 292M USD | Not meaningful (loss) | -213.6 % | 14.1 % | -60.5 % | 5.4x | -4.8 % | -77.2 % | ||
| 5 | 4894 | 2.1 | 1.5 | 296M USD | Not meaningful (loss) | -1478.4 % | -52.6 % | -15.8 % | 5.0x | — | -13.8 % | ||
| 6 | EVMN | 2.1 | 0.9 | 291M USD | Not meaningful (loss) | — | -100.0 % | -68.1 % | 1.3x | -31.3 % | -63.4 % | ||
| 7 | 6945 | 1.5 | N/A | 287M USD | Not meaningful (loss) | — | — | -22.4 % | 4.5x | -4.1 % | -7.9 % | ||
| 8 | GLSI | 1.5 | N/A | 283M USD | Not meaningful (loss) | — | — | -10656.2 % | — | -4.5 % | 134.2 % | ||
| 9 | 2617 | 1.5 | N/A | 294M USD | Not meaningful (loss) | -738.1 % | — | -36.0 % | 3.6x | -12.3 % | -96.8 % |
